These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418 [TBL] [Abstract][Full Text] [Related]
63. [Pharmacotherapy of inflammatory bowel disease]. Jojić N Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366 [TBL] [Abstract][Full Text] [Related]
64. IBD in 2013: enriching the therapeutic armamentarium for IBD. Danese S; Peyrin-Biroulet L Nat Rev Gastroenterol Hepatol; 2014 Feb; 11(2):84-6. PubMed ID: 24366229 [TBL] [Abstract][Full Text] [Related]
65. Current management of intestinal bowel disease: the role of surgery. Solina G; Mandalà S; La Barbera C; Mandalà V Updates Surg; 2016 Mar; 68(1):13-23. PubMed ID: 27067590 [TBL] [Abstract][Full Text] [Related]
66. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483 [TBL] [Abstract][Full Text] [Related]
67. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases. Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393 [TBL] [Abstract][Full Text] [Related]
68. Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease. Larsen MD; Qvist N; Nielsen J; Kjeldsen J; Nielsen RG; Nørgård BM J Crohns Colitis; 2016 Jun; 10(6):650-6. PubMed ID: 26802081 [TBL] [Abstract][Full Text] [Related]
69. Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy. Sokic-Milutinovic A; Milosavljevic T Dig Dis; 2024; 42(4):325-335. PubMed ID: 38096793 [TBL] [Abstract][Full Text] [Related]
70. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Tanaka M; Riddell RH; Saito H; Soma Y; Hidaka H; Kudo H Scand J Gastroenterol; 1999 Jan; 34(1):55-67. PubMed ID: 10048734 [TBL] [Abstract][Full Text] [Related]
71. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612 [TBL] [Abstract][Full Text] [Related]
73. [New molecules in the treatment of inflammatory bowel disease]. Chaparro M; Gisbert JP Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943 [TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251 [TBL] [Abstract][Full Text] [Related]
75. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center. Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991 [TBL] [Abstract][Full Text] [Related]
76. Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD. Berkovitch G; Cohen S; Lubetzky R; Singer D; Yerushalmy-Feler A BMC Pediatr; 2021 Feb; 21(1):63. PubMed ID: 33541320 [TBL] [Abstract][Full Text] [Related]
77. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Guerra Veloz MF; Vázquez Morón JM; Belvis Jiménez M; Pallarés Manrique H; Valdés Delgado T; Castro Laria L; Maldonado Pérez B; Benítez Roldán A; Perea Amarillo R; Merino V; Caunedo Álvarez Á; Argüelles Arias F Rev Esp Enferm Dig; 2018 Sep; 110(9):564-570. PubMed ID: 29893581 [TBL] [Abstract][Full Text] [Related]
78. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. Simian D; Fluxá D; Flores L; Lubascher J; Ibáñez P; Figueroa C; Kronberg U; Acuña R; Moreno M; Quera R World J Gastroenterol; 2016 Jun; 22(22):5267-75. PubMed ID: 27298570 [TBL] [Abstract][Full Text] [Related]
79. The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. Nguyen GC; Elnahas A; Jackson TD J Crohns Colitis; 2014 Dec; 8(12):1661-7. PubMed ID: 25107847 [TBL] [Abstract][Full Text] [Related]
80. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]